Safety of Combining Metoclopramide with Ondansetron

Evidence from Clinical Guidelines

The American Society of Clinical Oncology (ASCO) guidelines (2017 and 2020) list both metoclopramide (5-20mg) and ondansetron (8mg) as acceptable antiemetic options for radiation-induced nausea, with metoclopramide 5-20mg oral or IV and ondansetron 8mg oral or IV recommended for low-risk and minimal-risk radiation therapy 1, 2
The National Comprehensive Cancer Network (NCCN) guidelines (2010) recommend both medications for managing opioid-induced nausea, with metoclopramide 10-20mg PO and ondansetron 8mg PO listed as treatment options 3
The Multinational Association of Supportive Care in Cancer (MASCC) and European Society for Medical Oncology (ESMO) guidelines (2010) include both agents in their antiemetic recommendations for various clinical scenarios 4

Both ondansetron and metoclopramide can prolong the QT interval independently, with additive QT prolongation being a significant concern when combining these medications 5
The risk of serotonin syndrome is primarily relevant when either medication is combined with SSRIs or other serotonergic agents, with the National Comprehensive Cancer Network noting increased risk when metoclopramide is combined with serotonin reuptake inhibitors 6
Metoclopramide carries a risk of extrapyramidal side effects (dystonia, akathisia, tardive dyskinesia), which is not increased by ondansetron but should be monitored, with the use of the lowest effective dose of metoclopramide (5-10mg) and avoidance of prolonged use (>12 weeks) recommended 3, 6

When combining metoclopramide and ondansetron, limit ondansetron to 8mg to minimize QT risk, start with metoclopramide 10mg, check baseline ECG if the patient has cardiac disease or other risk factors, and monitor serum potassium and magnesium levels 1, 2, 5
Avoid using the combination in patients taking SSRIs unless benefits clearly outweigh risks, and prefer ondansetron over metoclopramide in this context 6